Heteroaryl Compounds Trapping Retinaldehyde for Macular Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds used to reduce A2E formation in retinal tissue are not potent enough and have short pharmacological half-lives, limiting their effectiveness in treating macular degeneration and other retinal diseases.
Innovation Solution
Development of heteroaryl compounds that effectively trap RAL, reducing A2E formation with improved potency and extended pharmacological half-life, thereby addressing the accumulation of A2E and lipofuscin in retinal tissue and VEGF signaling by RPE cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current compounds are used to reduce A2E formation, then A2E accumulation is reduced, but the compounds have short pharmacological half-lives and limited effectiveness
Solution Approach 1:
The patent modifies the chemical structure of existing compounds by introducing heteroaryl groups and various substituents (halogens, alkyl groups, alkoxy groups, etc.) to change the pharmacological parameters of the compounds. These structural modifications extend the pharmacological half-life while maintaining the ability to trap RAL and reduce A2E formation, directly resolving the contradiction between effectiveness and duration of action.
2Reliability
If current compounds are used to reduce A2E formation, then A2E accumulation is reduced, but the compounds are not potent enough
Solution Approach 1:
The patent employs systematic parameter changes in the chemical structure of RAL-trapping compounds by incorporating heteroaryl cores with various electron-withdrawing and electron-donating substituents. These modifications enhance the reaction energetics and equilibrium constants, thereby increasing the potency of the compounds in trapping RAL and reducing A2E formation, while maintaining acceptable pharmacological half-lives.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The heteroaryl compounds demonstrate enhanced reaction energetics and equilibrium constants, leading to more effective RAL trapping and prolonged activity, effectively reducing the risk and symptoms of macular degeneration and other retinal diseases.
Implementation Method 1
The compounds are designed to inhibit A2E biosynthesis by reducing the amount of free RAL available for reaction with PE in photoreceptor outer segments
Data Source
AI summary
The present invention is directed to compounds of formula (A):pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.